학술논문

UTILITY OF FIB-4, MRE, MRI-PDFF AND FIBROSCAN TO IDENTIFY PATIENTS WITH AT-RISK F2-F3 NASH BASED ON SCREENING DATA FROM A 2000 PATIENT BIOPSY CONFIRMED COHORT OF RESMETIROM PHASE 3 CLINICAL TRIAL, MAESTRO-NASH
Document Type
Journal
Source
HEPATOLOGY; OCT 2022, 76 pS92-pS94, 3p. Supplement: 1
Subject
Language
English
ISSN
15273350